Stem Cell Therapy

Stem Cell Therapy




A stem cell is essentially a “blank” cell, capable of becoming another more differentiated cell type in the body, such as a skin cell, a muscle cell, or a nerve cell; i.e. a hair stem cell can give a heart muscle cell or a nerve cell.

Microscopic in size, stem cells can be used to replace or even heal damaged tissues, as well as cells in the body.

Stem Cells treatment is the most advanced application of Functional and Regenerative Medicine. We use the patient’s stem cells to repair injured or degenerated tissues in various parts of the body, as required.

When there is a lesion or trauma at any point in the body, stem cells are “called” through appropriate neurochemical mechanisms and they begin to move and accumulate at the site of the lesion. Once they arrive at that point, the process of their transformation into cells of the destroyed tissue begins, and thus achieving regeneration of the area.

The pluripotent stem cells of our body can be transformed, when needed, in any type of cell. They can become muscle, skin, ligaments, or cartilage cells, or any type of cell needed to restore the damage. Stem Cells obey the laws of homeostasis, have intelligence and know what they need in order to create tissue with great accuracy. Moreover, they can identify any tissue that may be harmful to the body and have the ability to remove it.

They can serve as a built-in repair system for the human body, replenishing other cells as long as a person is still alive.

Embryonic stem cells have great “plasticity”, i.e. ability to differentiate in each type of tissue.

Adult stem cells can also be differentiated in each cell.

Adult stem cells are a “natural” solution. They naturally exist in our bodies, and they provide a natural repair mechanism for many tissues of our bodies. They belong in the microenvironment of an adult body, while embryonic stem cells belong in the microenvironment of the early embryo.

Adult stem cells have already been successfully used in human therapies for many years.

The therapies that have been used include: cancer, heart failure, hepatic failure and cirrhosis, renal failure, neurological diseases (multiple sclerosis, Parkinson’s disease), blood, orthopedic, ophthalmologic and autoimmune diseases (Type 1 Diabetes, Rheumatoid Arthritis, Behcet Disease, Lupus Erythematosus, Myasthenia, Sjogren Syndrome, Scleroderma, Alopecia Areata).



1.    Evans RW, Orians CE, Ascher ΝΙ. The potential supply of organ donors: an assessment of the efficiency of organ procurement efforts ίπ the United States. JAMA. 1992;267:239-246.
2.    Sanfilippo F, Vaughn WK, Peters TG, et al. Factors affecting the waiting time of cadaveric kidney transplant
candidates ίπ the United States. JAMA. 1992;267:247-252.
3.     United Network for Organ Sharing. The 1995 Annual Report of the U.S. Scientific Registry of Transplant
Recipients and the Organ Procurement and Transplantation Network. 1995.
4.    White D. Alteration of complement activity: a strategy for xenotransplantation. Trends Biotechnol. 1996;14:3-
5.     Reemtsma Κ, McCracken ΒΗ, Schlegel JV, Pearl Μ. Heterotransplantation of the kidney: two clinical experiences. Science. 1964;143:700-702.
6.       Auchincloss Η Jr, Sachs DH. Xenogeneic transplantation. Αππυ Rev Immunol. 1998;16:433-470.
7.       Steele DJR, Auchincloss Η Jr. Xenotransplantation. Annu Rev Med. 1995;46:345-360.
8.       PHS Guideline οπ Infectious Disease Issues ίπ Xenotransplantation, USPHS, January 19, 2001. Available at
btJR://WWW.fg!.hgov/cb_~rLguidelines.htm. Accessed May 31, 2002.
9.   Draft Guidance for Industry: Precautionary Measures to Reduce the Possible Risk of Transmission of
Zoonoses by Blood and Blood Products from Xenotransplantation Product Recipients and Their Contacts,
FDA, December 23, 1999. Avaίlable at bllp:// Accessed May 31,2002.
 10. Platt JL. Α perspective οπ xenograft rejection and accommodation. Immunol Rev. 1994;141: 127 -149.
 11.Inverardi Ι, Pardi R. Early events ίπ cell-mediated recognition of vascularized xenografts: cooperative
interactions between selected Iymphocyte subsets and natural antibodies. Immunol Rev. 1994;141:71-93.
 12. Bach FH, Winkler Η, Ferran C, Hancock νννν, Robson SC. Delayed xenograft rejection. Immunol Today.
1996; 17:379-384.
 13. Azimzadeh Α, Wolf Ρ, Dalmasso ΑΡ, et al. Assessment of hyperacute rejection ίπ a rat-to-primate cardiac
xenograft model. Transplantation. 1996;61:1305-1313.
 14.Siegel JB, Grey ST, Lesnikoski Β-Α, et al. Xenogeneic endothelial cells activate human prothrombin.
Transplantation. 1997;64:888-896.
15.Samuelsson ΒΕ, Rydberg L, Breimer ΜΕ, et al. Natural antibodies and human xenotransplantation. Immunol
Rev. 1994;141 :151-168.’
16.  Parker W, Saadi S, Lin SS, Holzknecht ΖΕ, Bustos Μ, Platt JL. Transplantation of discordant xenografts: a
challenge revisited. Immunol Today. 1996;17:373-378.
17.  Wang Η, DeVries Μ, Deng S, et al. The axis of interleukin 12 and gamma interferon regulates acute vascular
xenogeneic rejection. Nat Med. 2000;6:549-554.
18.  Bach FH, Ferran C, Hechenleitner Ρ, et al. Accommodation of vascularized xenografts: expression of
“protective genes” by donor endothelial cells ίπ a host Th2 cytokine env!ronment. Nat Med. 1997;3:196-204.
19.Sykes Μ, Lee LA, Sachs DH. Xenograft tolerance. Immunol Rev. 1994;141:245-276.
20.Hashimoto W, Takeda Κ, Anzai R, et al. Cytotoxic ΝΚ1.1 Ag+ alpha beta Τ cells with intermediate TCR
induced ίπ the lίνθΓ of mice by IΙ-12. J Immunol. 1995; 154:4333-4340.
21. Wallgren AC, Karlsson-Parra Α, Korsgren Ο. The main infιltrating cell ίπ xenograft rejection is a CD4+
macrophage and not a Τ Iymphocyte. Transplantation. 1995;60:594-601.
 22.Fryer JP, Leventhal JR, Dalmasso ΑΡ, et al. Cellular rejection ίπ discordant xenografts when hyperacute
rejection is prevented: analysis using adoptive and passive transfer. Transpllmmunol. 1994;2:87-93.
23.Friedman Τ, Shimizu Α, Smith RN, et al. Human CD4+ Τ cells mediate rejection of porcine xenografts. J
Immunol. 1999;162:5256-5262.
24.Sawada Τ, DellaPelle ΡΑ, Seebach JD, Sachs DΗ, Colvin RB, lacomini J. Human ceII-mediated rejection of
porcine xenografts ίπ an immunodeficient mouse model. Transplantation. 1997;63: 1331-1338.
25. Lίn γ, Vandeputte Μ, Waer Μ. Natural kίller cell- and macrophage-mediated rejection concordant xenografts
ίn the absence ofT and Β cell responses. J Immunol. 1997;158:5658-5667.
26.Lawson JH, Daniels LJ, Platt JL. The evaluation of thrombomodulίn activity ίπ porcine to human
xenotransplantation. Transplant Proc. 1997;29:884-885.
27  ViIIinger F, Brar SS, Mayne Α, Chikkala Ν, Ansari ΑΑ. Comparative sequence analysis of cytokine genes
from human and nonhuman primates. J Immunol. 1995; 155:3946-3954.
28.Goddard MJ, Foweraker JE. Xenotransplantation – 2000. J Clin Pathol. 2000;53:44-48.
29.Breimer ΜΕ. Physiologic incompatibilities ίπ discordant xenotransplantation. Transplant Proc. 1999;31:905-
30.Johnsson C, Andersson Α, Bersztel Α, Karlsson-Parra Α, Gannedahl G, Tufveson G. Successful
retransplantation of mouse-to-rat cardiac xenografts under immunosuppressive monotherapy with
cyclosporine. Transplantation. 1997;63:652-656.
Starzl ΤΕ, Valdivia ιΑ, Murase Ν, et al. The biological basis of and strategies for clίnical χenotranspJantatio
Immunol 1994;141 :213-244.
Cozzi Ε, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med.
1995; 1 :964-966.
Byrne GW, McCurry KR, Martin MJ, McCleIIan SM, Platt JL, Logan JS. Transgenic pigs eχpressing human
CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage.
Transplantation. 1997;63: 149-155.
Mollnes ΤΕ, Fiane ΑΕ. Xenotransplantation: how to overcome the complement obstacle? Mollmmunol.
Cooper DKC, Koren Ε, ΟΓίοl R. Oligosaccharides and discordant χenotransplantation. Jmmunol Rev.
Sandrin MS, McKenzie IFC. Gal alpha(1 ,3)Gal, the major χenoantigen(s) recognised ίπ pigs by human
natural antibodies. Immunol Rev. 1994;141 :167-190.
Joziasse DH, ΟΓίοl R. Xenotransplantation: the importance of the Gal alpha1 ,3Gal epitope ίπ hyperacute
vascular rejection. Biochim Biophys Acta. 1999; 1455:403-
Costa C, Zhao Ι, Burton ννν, et al. Eχpression of the human alpha1 ,2-fucosyltransferase ίπ transgenic pigs
modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cyto
FASEB J. 1999;13:1762-1773
Costa C, Zhao Ι, Decesare S, Fodor WL. Comparative analysis of three genetic modifications designed to
inhibit human serum mediated cytolysis. 1999;6:6-16.
Byrne GW, McCurry KR, Kagan D, et al. Protection of χenogeneic cardiac endothelium from human
complement by ωφτεεείοη of CD59 ΟΓ DAF ίπ transgenic mice. 1995;60:1149-1156.
Candinas D, Lesnikoski Β-Α, Robson SC, et al. Effect of repetitive high-dose treatment with soluble
complement receptor type 1 and cobra venom factor οπ discordant xenograft surνival. Transplantation.
Kobayashi Τ, Taniguchi S, Neethling FA, et al. Delayed χenograft rejection of pig-to-baboon cardiac
transplants after cobra venom factor therapy. Transplantati 1997;64:1255-1261.
Koyamada Ν, Miyatake Τ, Candinas D, et al. Apyrase administration prolongs discordant χenograft surνiν2
Transplantation. 1996; 62: 1739-1743.
Brenner Ρ, Reichenspurner Η, Schmoeckel Μ, et al. Ig-Therasorb immunoapheresis ίπ orthotopic
χenotransplantation of baboons with landrace pig hearts. 2000;69:208-214.
Manez R, Crespo F, Gonzalez Ε, et al. ΝeutralίΖatίοnρf anti- alphaGalactosyl antibodies without
immunosuppression prevents hyperacute rejection but not acute vascular rejection of pig organs transpl
into baboons. Transplant Proc. 2000;32:888-
Monaco ΑΡ, Maki Τ. Islet transplantation using immunoeχclusion methods. Transplant Proc. 1996;28:2
Sun Υ-Ι, Ma Χ, Zhou D, Vacek Ι, Sun ΑΜ. Porcine pancreatic islets: isolation, microencapsulation, and
xenotransplantation. Artif Organs. 1993;17:727-733.
Chen S, Kahaku Ε, Watanabe F, et a Treatment of severe Iίver faίlure with a bioartificiallίver. Αππ Ν Υ
Sci. 1997;831 :350-360.
Chappell DB, Restifo ΝΡ. Τ cell-tumor cell: a fatal interaction. Cancer Immunollmmunother. 1998;47:65-
Stockmann HBAC, Hiemstra CA, Marquet RL, Ijzermans JNM. Eχtracorporeal perfusion for the treatme
acute lίνer faίlure. Αππ Surg. 2000;231 :460
Yagi Τ, Satoh S, Kanazawa Α, et al. Eχtracorporeal χenoperfusion of the pig lίνer as a lίνer assist device:
effects of prostaglandin Ε 1 and soluble receptor type 1. Transplant Proc. 1998;30:74-75.
Levy MF, Crippin J, Sutton S, et al. Lίver allotransplantation after eχtracorporeal hepatic support with
transgenic (hCD55/hCD59) porcine lίνers: clinical results and lack of pig-to-human transmission of the
porcine endogenous retrovi Transplantation. 2000;69:272-280.
Eastlund Τ. Infectious disease transmission through cell, tissue and organ transplantation: reducing the
through donor selection. Cell Transplant. 1995;4:455-477.
Chapman ΙΕ, Folks ΤΜ, Salomon DR, Patterson ΑΡ, Eggerman ΤΕ, Noguchi PD. Xenotransplantation χenogeneic infections. Ν Engl J Med. 1995;333:1498-1501.
AIIan JS. Xenotransplantation at a crossroads: prevention versus progress. Nat Med. 1996;2:18-21.
Fishman JA. The risk of infection ίπ χenotransplantation. Αππ Ν Υ Acad Sci. 1998; 862:45-5
Chapman ΙΕ, Heneine W, Switzer W, Sandstrom Ρ, Folks ΤΜ. Xenotransplantation: the potential for
χenogeneic i Transplant Proc. 1999;31 :909-910.
Chapman ΙΕ. Xenogeneic infections and public health. Clin Εκρ Pharmacol Physiol. 1999;26:1005-1008.
Holmes GP, Chapman LΕ, Stewart JA, Straus SE, Hillίard JK, Davenport DS. Guidelines for the preven –
and treatment of B-virus infections ίπ eχposed persons. The Β Virus Working Group. Clin Infect Dis.
Patterson ΑΡ, Bloom ΕΤ, Chapman ΙΕ. Clinical trials ίπ χenotransplantation: the public health promises–
challenges of an emerging technology. J Irish ColI Phys Surg. 1999;28:222-227